Antithrombotic therapy, including antiplatelet and anticoagulant agents, is the cornerstone of
pharmacological treatment to optimize clinical outcomes in patients with ST-segment …

Antithrombotic therapy is an essential component in the optimisation of clinical outcomes in
patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous …

Objectives: The study sought to compare the clinical efficacy and safety of P2Y12 inhibitors
in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary …

Background Robust comparisons between oral P2Y12 inhibitors (clopidogrel, prasugrel,
ticagrelor) in ST-elevation myocardial infarction (STEMI) patients who undergo primary …

Background There is a paucity of real-world outcome data comparing clopidogrel, prasugrel
and ticagrelor in primary percutaneous coronary intervention (PPCI) for ST-segment …

Background Prasugrel compared to clopidogrel has been shown to improve outcome in
patients with ST elevation myocardial infarction (STEMI) in the TRITON-TIMI 38 trial. Little is …

Prasugrel is more potent than clopidogrel, but it is not known whether this translates into
clinical benefit in patients undergoing primary percutaneous coronary intervention (PCI) with …

Background Mechanical reperfusion with stenting for ST-elevation myocardial infarction
(STEMI) is supported by dual antiplatelet treatment with aspirin and clopidogrel. Prasugrel, a …

Objectives: This study sought to evaluate the efficacy of prasugrel versus clopidogrel in ST-
segment elevation myocardial infarction (STEMI) by the timing of percutaneous coronary …

Aims Early initiation of dual antiplatelet therapy (DAPT) is guideline-recommended.
MULTIPRAC was conducted to gain insights into the use patterns and outcomes of pre …